Home
Journal Information
About
Aims and Scope
Contacts and Editorial Office
Editorial Board
Editor in Chief
Indexing info
Publisher
Disclaimer
Journal license
Publication Ethics
SDNP's policy
Open Access
Conflicts of Interest
Copyright
Guidelines
For Authors-new
For Reviewers
Peer Review Process in JNP
Peer Review Process flowchart in JNP
Checklist for review
Call for Papers
Editorial Workflow
Publication Ethics and Malpractice Statement
Human and animal right
Informed Consent
New Page
Contact Us
Create Account
Login
Title
Author
Abstract
Keywords
First Name
Last Name
Search
ISSN
:
2251-8363
eISSN
:
2251-8819
J Nephropathol
. 2017;6(3): 134-137. doi:
10.15171/jnp.2017.23
PMID:
28975092
PMCID:
PMC5607973
Case Report
Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
Gebran Khneizer, Ahmad Al-Taee, Bahar Bastani *
Cited by CrossRef: 7
1- Hanna R, Tran N, Patel S, Hou J, Jhaveri K, Parikh R, Selamet U, Ghobry L, Wassef O, Barsoum M, Bijol V, Kalantar-Zadeh K, Pai A, Amin A, Kupperman B, Kurtz I. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
Front Med
. 2020;7
[Crossref]
2- Phadke G, Hanna R, Ferrey A, Torres E, Singla A, Kaushal A, Kalantar-Zadeh K, Kurtz I, Jhaveri K. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration. 2021;14(10):2158
[Crossref]
3- Kenworthy J, Davis J, Chandra V, Clark J, Desmond M. Worsening Proteinuria Following Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema.
Journal of VitreoRetinal Diseases
. 2019;3(1):54
[Crossref]
4- Grechukhina K, Chebotareva N, Krasnova T. Nephrotoxicity of anti-angiogenesis drugs.
Terapevticheskii arkhiv
. 2020;92(6):93
[Crossref]
5- Yang S, Su Y, Lim C, Huang J, Hsu S, Wu L, Chang Y, Hung J. Risk of dialysis in patients receiving intravitreal antiāvascular endothelial growth factor treatment: a population-based cohort study.
Aging
. 2022;14(12):5116
[Crossref]
6- Hanna R, Lopez E, Hasnain H, Selamet U, Wilson J, Youssef P, Akladeous N, Bunnapradist S, Gorin M. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. 2019;12(1):92
[Crossref]
7- Hanna R, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emergingĀ evidence.
Kidney International
. 2019;96(3):572
[Crossref]
8- Shye M, Hanna R, Patel S, Tram-Tran N, Hou J, Mccannel C, Khalid M, Hanna M, Abdelnour L, Kurtz I. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. 2020;13(6):969
[Crossref]
9- Bevacizumab.
Reactions Weekly
. 2017;1657(1):80
[Crossref]
10- Hanna R, Ahdoot R, Kim M, Jhaveri K, Kalantar-Zadeh K, Kurtz I. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. 2022;31(1):47
[Crossref]
11- Grechukhina K, Chebotareva N, Zhukova L, Krasnova T. Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs.
Terapevticheskii arkhiv
. 2021;93(6):661
[Crossref]
12- Yau A, Conklin E, Campion V. Secondary Membranous in the Cancer Patient.
Journal of Onco-Nephrology
. 2022;6(1-2):29
[Crossref]
Submit Your Paper
Instructions for Authors
Aims and Scope
Editorial Board
Publication Ethics
Editorial Policies
Publication Fee
Process for Identification of and Dealing with Allegations of Research Misconduct
Archive
Indexing Information
Member of
Follower of